SUNRISE, Fla., May 15 /PRNewswire-FirstCall/ -- Bioheart, Inc. (Nasdaq:
BHRT) a biotechnology company that is focused on the development of
autologous (patient-derived) cell therapies and devices for the treatment
of chronic and acute heart damage, today announced financial results for
the quarter ended March 31, 2008.
-- On February 19, 2008, the Company completed its initial public offering
(IPO) of common stock for gross proceeds of approximately $5.8 million.
The net cash proceeds from the IPO are expected to be utilized to
commence full-scale enrollment in a Phase II/III MARVEL Clinical Trial
of MyoCell(R) in the U.S. and Europe.
-- On January 18, 2008, the final 12-month results of the MYOHEART Trial,
a Phase I dose-escalation study of MyoCell in the United States, the
Company's lead product candidate, were presented at the Fourth Annual
International Conference on Cell Therapy for Cardiovascular Diseases
(NY). The results, presented by Warren Sherman, MD, Principal
Investigator and Director, Cell-based Endovascular Therapies, Columbia
University Medical Center, NY, suggested trends in improved quality of
life measurements sustained out to 12 months following treatment,
without unexpected rates of serious adverse events related to the
therapy given its patient population.
-- On April 1, 2008, the final six-month results of the Phase II SEISMIC
Trial of MyoCell in Europe, was presented during the clinical trial
sessions at the American College of Cardiology. These results suggested
that MyoCell is a safe and potentially effective alternative treatment
to standard medical therapy alone for improving heart function among
patients with previously implanted cardiac devices who are experiencing
|SOURCE Bioheart, Inc.|
Copyright©2008 PR Newswire.
All rights reserved